Back to search

Article

DDX58 deficiency leads to doxorubicin chemotherapy resistance by hindering Type I IFN signalling-mediated apoptosis in TNBC

2022-10-17

Abstract excerpt

Triple-negative breast cancer (TNBC) lacks therapeutic targets for precision treatment, making cytotoxic chemotherapy still the primary treatment, but drug resistance often occurs. Unveiling mechanisms for TNBC chemoresistance and trying to reverse this process would undoubtedly improve the overall outcomes. Through three GEO datasets, we found that DDX58 gene was associated with pathological Complete Response (pC...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
9716ea75-f891-5cdb-b42e-f87fa96adcda
DOI
10.21203/rs.3.rs-2108631/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
DDX58 deficiency leads to doxorubicin chemotherapy resistance by hindering Type I IFN signalling-mediated apoptosis in TNBCDOI 10.21203/rs.3.rs-2108631/v1
Select a neighboring publication to make it the new centre.